Emergent BioSolutions

$80.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.24 (+1.57%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EBS and other stocks, options, and ETFs commission-free!

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD. The listed name for EBS is Emergent Biosolutions, Inc.

CEO
Robert G. Kramer
Employees
1,834
Headquarters
Gaithersburg, Maryland
Founded
1998
Market Cap
4.26B
Price-Earnings Ratio
25.61
Dividend Yield
Average Volume
665.32K
High Today
$81.75
Low Today
$78.88
Open Price
$79.66
Volume
515.71K
52 Week High
$137.61
52 Week Low
$46.37

Collections

EBS Earnings

-$0.13
$0.64
$1.42
$2.19
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 18, After Hours

You May Also Like